Skip to main content
. 2017 Oct 3;11:2905–2919. doi: 10.2147/DDDT.S114932

Table S1.

Glycemic efficacy of ertugliflozin: data from Phase III clinical trials

Study Arms Mean change from baseline HbA1c %
HbA1c difference vs PBO
To end of main study
To end of extension
To end of main study
To end of extension
LS mean (95% CI) LS mean (95% CI) LS mean (95% CI) LS mean (95% CI)
VERTIS MONO1,2 PBO (n=153) 0.2 (0.02–0.37)
ERTU 5 mg (n=155) −0.79 (−0.95, −0.63) −0.74 (−0.89, −0.58) −0.99* (−1.22, −0.76)
ERTU 15 mg (n=155) −0.96 (−1.12, −0.80) −0.89 (−1.05, −0.74) −1.16* (−1.39, −0.93)
VERTIS MET3 PBO (n=209)
ERTU 5 mg (n=207) −0.70* (−0.87, −0.53)
ERTU 15 mg (n=205) −0.88* (−1.05, −0.71)
VERTIS FACTORIAL4,5 ERTU 5 mg (n=250) −1.0 (−1.1, −0.9) −0.96 (−1.10, −0.82)
ERTU 15 mg (n=248) −1.1 (−1.2, −1.0) −0.93 (−1.07, −0.79)
SITA 100 mg (n=247) −1.1 (−1.2, −0.9) −0.82 (−0.97, −0.68)
ERTU 5 mg + SITA 100 mg (n=243) −1.5a (−1.6, −1.4) −1.36 (−1.50, −1.22)
ERTU 15 mg + SITA 100 mg (n=244) −1.5a (−1.6, −1.4) −1.39 (−1.53, −1.25)
VERTIS SITA6 PBO (n=96) −0.44 (−0.69, −0.19)
ERTU 5 mg + SITA 100 mg (n=98) −1.60 (−1.82, −1.39) −1.16* (−1.49, −0.84)
ERTU 15 mg + SITA 100 mg (n=96) −1.68 (−1.90, −1.46) −1.24* (−1.57, −0.91)
VERTIS SITA 27,8 PBO (n=153) −0.1 (−0.23, 0.04) 0.02 (−0.15, 0.19)
ERTU 5 mg (n=156) −0.78 (−0.91, −0.65) −0.75 (−0.90, −0.59) −0.68* (−0.87, −0.50) −0.76 (−0.98, −0.54)
ERTU 15 mg (n=155) −0.86 (−0.99, −0.72) −0.81 (−0.97, −0.66) −0.76* (−0.95, −0.58) −0.83 (−1.05, −0.61)

Mean change from baseline HbA1c % HbA1c difference vs glimepiride

VERTIS SU9 ERTU 5 mg (n=448) −0.6 NA 0.2 (0.1, 0.3)
ERTU 15 mg (n=440) −0.6 NA 0.1 (−0.0, 0.2)*
Titrated glimepiride (n=437) −0.7 NA

Notes:

*

p<0.001.

a

p<0.004 versus individual treatment.

Abbreviations: ERTU, ertugliflozin; SITA, sitagliptin; PBO, placebo; HbA1c, glycated hemoglobin.